Methamphetamine is the fourth most frequently reported compound associated with drug abuse on admission of patients to treatment centres after cocaine, heroin and marijuana. It is metabolized in the organism with a reaction that is catalyzed by cytochrome P450, mainly by the CYP2D and CYP3A subfamily, 4-hydroxyamphetamine and amphetamine being dominant metabolites. The present pharmacokinetic study was undertaken to investigate the possible influence of methamphetamine (10 mg/kg, i.p., once daily for six days) on the pharmacokinetics of dextromethorphane as a model substrate for rat cytochrome P-4502D2 and midazolam as a model substrate for CYP3A1/2. Animals received a single injection of dextromethorphane (10 mg/kg) or midazolam (5 mg/kg) in the tail vein 24 h after the last dose of methamphetamine or administration of placebo. The results of pharmacokinetic analysis showed a significantly increased rate of dextrorphane and 3-hydroxymorphinan formation, and a marked stimulatory effect of methamphetamine on CYP2D2 metabolic activity. Similarly, the kinetics of midazolam's metabolic conversion to hydroxy derivates of midazolam indicated a significant increase in CYP3A1/2 activity. The results showed that the administration of methamphetamine significantly stimulated the metabolic activity of CYP2D2 as well as that of CYP3A1/2. With regard to the high level of homology between human and rat CYP isoforms studied, the results may have a clinical impact on future pharmacotherapy for methamphetamine abuse.

Department of Pharmacology University of Masaryk Faculty of Medicine Brno Czech Republic

Zobrazit více v PubMed

Br J Clin Pharmacol. 1994 Sep;38(3):243-8 PubMed

Clin Pharmacol Ther. 1999 Jul;66(1):40-50 PubMed

Mol Pharmacol. 1989 Jul;36(1):89-96 PubMed

Arch Biochem Biophys. 1958 Jun;75(2):376-86 PubMed

Ther Drug Monit. 1988;10(4):490-8 PubMed

J Subst Abuse. 2001;13(1-2):119-26 PubMed

Hawaii Med J. 2004 Jan;63(1):8-13, 25 PubMed

Pharmacogenetics. 1993 Aug;3(4):197-204 PubMed

J Oral Maxillofac Surg. 1992 Oct;50(10):1052-4 PubMed

Pharmacogenetics. 1996 Feb;6(1):1-42 PubMed

Life Sci. 1998;63(19):1685-92 PubMed

Xenobiotica. 1992 Jan;22(1):83-103 PubMed

Chem Res Toxicol. 1992 May-Jun;5(3):401-6 PubMed

Xenobiotica. 2004 Sep;34(9):811-34 PubMed

Biochem Pharmacol. 1993 Feb 24;45(4):833-9 PubMed

Ann Intern Med. 1993 Oct 1;119(7 Pt 2):707-13 PubMed

J Biol Chem. 1964 Jul;239:2370-8 PubMed

AIDS Care. 2003 Dec;15(6):775-85 PubMed

J Forensic Sci. 1983 Jan;28(1):18-31 PubMed

Xenobiotica. 1994 Dec;24(12):1151-75 PubMed

Drug Metab Dispos. 1996 Sep;24(9):940-7 PubMed

Biochem Pharmacol. 1997 Jun 1;53(11):1605-12 PubMed

J Subst Abuse Treat. 2002 Apr;22(3):149-56 PubMed

Antivir Ther. 2000 Mar;5(1):19 PubMed

Biochem Biophys Res Commun. 1988 Apr 15;152(1):411-6 PubMed

Drug Metab Dispos. 1995 Jun;23(6):610-4 PubMed

Ther Drug Monit. 1992 Feb;14 (1):1-8 PubMed

J Subst Abuse Treat. 1996 Nov-Dec;13(6):483-6 PubMed

J Chromatogr B Biomed Appl. 1996 Mar 29;678(1):113-28 PubMed

Curr Top Med Chem. 2001 Nov;1(5):403-25 PubMed

J Pharmacol Toxicol Methods. 2000 Jan-Feb;43(1):41-54 PubMed

Clin Pharmacokinet. 1998 Nov;35(5):361-90 PubMed

Biochem Pharmacol. 1992 Dec 1;44(11):2089-98 PubMed

Biochem J. 1972 Aug;129(1):11-22 PubMed

Biochem Pharmacol. 2002 Mar 1;63(5):889-96 PubMed

Br J Anaesth. 1994 Nov;73(5):658-61 PubMed

J Biol Chem. 1962 Apr;237:1375-6 PubMed

Drug Metab Rev. 2002 Feb-May;34(1-2):17-35 PubMed

J Psychopharmacol. 2000;14(3):244-50 PubMed

Xenobiotica. 1984 Nov;14(11):867-75 PubMed

Drug Alcohol Depend. 2001 Mar 1;62(1):91-5 PubMed

J Cell Mol Med. 2002 Apr-Jun;6(2):189-98 PubMed

Annu Rev Pharmacol Toxicol. 2001;41:535-67 PubMed

Obes Res. 1999 Jul;7(4):370-8 PubMed

Biochem Pharmacol. 1994 Mar 29;47(7):1151-6 PubMed

Cell Mol Life Sci. 2001 May;58(5-6):737-47 PubMed

J Psychoactive Drugs. 2000 Apr-Jun;32(2):137-41 PubMed

Biochem Pharmacol. 1994 Jul 5;48(1):173-82 PubMed

Biopharm Drug Dispos. 1997 Apr;18(3):227-40 PubMed